Skip to main content

Chronic Lymphocytic Leukemia

Featured Article
William G. Wierda, MD, PhD, professor, Department of Leukemia, University of Texas MD Anderson Cancer Center, discusses the results of the Phase II CAPTIVATE study, and highlights how the use of…
Whether on treatment regimens or watch-and-wait, researchers recently found that patients with chronic lymphocytic leukemia had significantly impaired quality of life compared with age-matched…

Insights

Based on a median follow-up of four years, John Allen, MD, assistant professor of Medicine in the Division of Hematology and Medical Oncology at Weill Cornell Medicine, New York-Presbyterian Hospital, explains how first-line ibrutinib-based…
William G. Wierda, MD, PhD, professor, Department of Leukemia, University of Texas MD Anderson Cancer Center, discusses the results of the Phase II CAPTIVATE study, and highlights how the use of Ibrutinib plus Venetoclax confers high rates of…
Lindsey Roeker, MD, physician, Memorial Sloan Kettering Cancer Center, breaks down the treatment landscape and disease burden commonly faced among patients with chronic lymphocytic lymphoma.
Back to Top